Safety and Quality of Life of CDK4/6 Inhibitors Therapy for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer: A Multicenter Cross-Sectional Survey in China

    May 2025 in “ BMC Cancer ”
    Benlong Yang, Zhengkui Sun, Quchang Ouyang, Zhongsheng Tong, Shu Wang, Hongyuan Li, Zhaofeng Niu, Yiding Chen, Linxiaoxi Ma, Hao‐Qi Wang, Mu Tang, Zheyu Hu, Xueqiang Gao, Xuming Wang, Fei Xie, Qiao Cheng, Yong Shen, Cuizhi Geng, Haibo Wang, Jiong Wu
    TLDR CDK4/6 inhibitors affect safety and quality of life differently, requiring careful use.
    This study surveyed 1,254 Chinese patients with HR+/HER2- advanced breast cancer undergoing CDK4/6 inhibitor therapy to assess treatment patterns, adverse events, and quality of life. The most common adverse events were leukopenia (63.30%) and neutropenia (58.73%), with fatigue (34.13%), alopecia (14.02%), and weakness (11.30%) being the most reported symptomatic events by patients. Alopecia incidence was notably lower in patients treated with dalpiciclib compared to palbociclib and abemaciclib. Quality of life assessments revealed that palbociclib users had lower breast symptom scores than those on abemaciclib. Alopecia significantly affected body image and other quality of life aspects. The study concludes that the safety and quality of life impacts of CDK4/6 inhibitors vary, highlighting the need for careful consideration in clinical practice.
    Discuss this study in the Community →

    Research cited in this study

    2 / 2 results